A healthy immune system depends on inhibitory receptors. Inhibitory receptor medicines are currently at the forefront of cancer treatment due to the fact that overexpression of inhibitory receptors might impair T cell responses. Antibodies that target the inhibitory receptors PD1 and CTLA4 have demonstrated encouraging effects in a number of malignancies in recent years. However, due to individual differences, not all cancer patients benefit from these medications, and therapies that target different immune checkpoints are receiving a lot of attention. Our initiative focuses on cutting-edge cancer immunotherapies that target TIGIT, an immunological checkpoint that inhibits immune activity and is crucial for immune suppression.

For more: cancer immunotherapy targeting TIGIT